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Abstract
Skin ulcers are a dangerous and uncommon complication of vasculitis. We describe the case of a teenager
suffering from Systemic Lupus Erythematosus with digital ulcer resistant to conventional therapy, treated success-
fully with Hyperbaric Oxygen Therapy. The application of hyperbaric oxygen, which is used for the treatment of
ischemic ulcers, is an effective and safe therapeutic option in patients with ischemic vasculitic ulcers in combina-
tion with immunosuppressive drugs. Further studies are needed to evaluate its role as primary therapy for this
group of patients.
Introduction
Vasculitis is a heterogeneous group of diseases character-
ized by inflammatory processes of the blood vessel wall
resulting in the alteration of blood flow and vascular
damage. The vessels involved are of different sizes
(arteries, arterioles, venules, capillaries). Resulting syn-
dromes are the consequence of tissue ischemia, vascular
damage and systemic inflammation. Most vasculitis is
mediated by the vascular deposition of immune com-
plexes (IC), abnormal cell-mediated immune responses,
antibodies against endothelial cells or against lysosomal
enzymes of neutrophils. Vasculitis may be primary or
secondary to connective tissue and intestinal diseases,
medications, tumors or athopy. Vasculitic skin ulcers are
clinical manifestations of ischemic injury, and are usually
treated medically by controlling the underlying disease
with immunosuppressants and systemic vasodilators [1].
Hyperbaric oxygen therapy (HBOT) is used as primary or
adjuvant therapy in various clinical conditions, including
cutaneous vasculitic ulcers that are resistant to immuno-
suppressive therapy [2]. We present a case of refractory
vasculitic ulcer responding to hyperbaric oxygen (HBO),
which was used in combination with immunosuppressive
therapy. We decided to treat the infected ulcer of the
patient with HBOT not only because it improves the
oxygenation of ischemic tissues and exerts beneficial
effects on vascular inflammatory response by regulating
the chemotaxis of leukocytes, but also because it facili-
tates the healing process of infected wounds promoting
the deposition of collagen, angiogenesis, epithelialization
and facilitating the oxygen-dependent killing by
leukocytes.
Case report
In mid February 2008 a 14 year old girl came under our
observation. She had been suffering for about 3 months
from persistent fever (38 ° C), weight loss (9 kilos), head-
ache and asthenia and was previously treated with several
courses of antibiotics and prednisone. Family history
shows that her paternal grandmother suffers from sclero-
derma, her paternal grandfather from rheumatoid arthritis,
her maternal grandmother from autoimmune thrombocy-
topenia, and her mother from thyroiditis. At admission,
she had a body weight of 45 kg (10
th -25
th percentile) and
a height of 154 cm (10
th -25
th percentile). Physical exami-
nation revealed a rash on the face, livedo reticularis, acro-
cyanosis at the first and second toe of the left foot,
arthritis in knees and ankles. Blood tests showed: anemia
(hemoglobin 10.5 gr/dl), leukocitopenia (3300/μl) with
lymphopenia (30%), normal platelet count (289000/μl),
increased inflammatory indexes (erythrocyte sedimenta-
tion rate 53 mm/1 hour; C-reactive protein 1,44 mg/dl);
increased serum IgG (2270 mg/dl), lengthening of
prothrombin time (57.5 seconds), reduced serum iron
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(9 mg/dl). Urinalysis excluded renal involvement, and
instrumental examinations (chest x-ray, abdominal ultra-
sound, echocardiography) ruled out the presence of ser-
ositis or other signs of disease. An eye examination,
echocolordoppler of lower limbs and capillaroscopy were
also negative. A diagnosis of Systemic Lupus Erythemato-
sus (SLE) was considered and confirmed, according to the
diagnostic criteria laid down by American College of
Rheumatology, for the presence of antinuclear antibodies
(1:1280, homogeneous appearance), anti-dsDNA (107 IU/
ml; normal < 30), anti-Sm (129 AU/ml, normal <30), anti-
Sm/RNP (120 AU/ml, normal <30), lupus anticoagulant
(1.48; normal 0-1.3) and anticardiolipin antibodies (25 U/
ml, normal up to 20). Her lupus anticoagulant and anticar-
diolipin antibodies were positive on one occasion, but sub-
sequently negative with no other evidence to suggest anti-
phospholipid syndrome. The patient was discharged with
the following therapy: prednisone (60 mg daily); hydroxy-
chloroquine (200 mg); anti-aggregating platelet therapy
(acetyl salicylic acid); ranitidine; vitamin D3 and calcium
carbonate. After two weeks of therapy there was an
improvement in the symptoms with normalization of
biochemical indices of inflammation but a worsening of
peripheral cyanosis, with the appearance of an intensely
painful and infected ischemic ulcer on the plantar surface
of the second toe of the left foot. Echocolordoppler and
capillaroscopy were again performed and were both nega-
tive. A local ulcer treatment was started with medications
a n dc l e a n s i n gp e r f o r m e db yac o n s u l t a n ts u r g e o n .T h e
ulcer, oval in shape, evolved in a pejorative sense at a
distance of 3 months after onset, reaching a maximum
diameter of about 1 centimeter. For this reason, and
because of the deepening of the lesion and the risk of
osteo-tendinous impairment, it was decided to associate
with the medical therapy a course of HBOT, with a proto-
col of 5 weekly sessions of 90 minutes at a pressure of 2.6
atmospheres absolute (ATA). Before starting the hyperba-
ric therapy, the ulcer appeared painful and oval shaped
with regular margins. It was covered by an infected eschar
and the surrounding skin was cold, thick and ranging
from deep red to bluish in color. After a week of therapy,
the cyanosis disappeared (figures 1 and 2), while the ulcer
healed after 16 sessions. The HBO was well tolerated by
the patient and 32 sessions were carried out in total with-
out any side effects (figure 3). From the interruption of
hyperbaric therapy, there were no relapses in the follow-
i n gm o n t h s .A f t e rf o u rw e e k sf r o mt h eb e g i n n i n go f
the immunosuppressive therapy, the daily dosage of pre-
dnisone was reduced by 5 mg every 15 days; and when it
reached 20 mg/day, it was further reduced by 2.5 mg every
four weeks until the current dose of 10 mg/day. The
immunosuppressive therapy was well tolerated by the
patient, blood tests were normal and there have been no
new flares of the disease so far.
Discussion
Vasculitic skin ulcers are a manifestation of muscular-
vessel vasculitis, and are very painful and difficult to
manage. They are usually treated by medical therapy
with systemic anti-inflammatory drugs, steroids and
immunosuppressants. For the treatment of refractory
vasculitic skin ulcers the use of prednisone combined
with other drugs such as methotrexate, azathioprine,
mycophenolate mofetil, cyclophosphamide or hydroxy-
chloroquine is recommended. Even the administration
Figure 1 Ulcer as it appears after 5 sessions of HBO.
Figure 2 Toes as they appear after 5 sessions of HBO.
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been effective in several case reports [1]. Other promis-
ing therapeutic options for these patients are vasodila-
tors such as antagonists of endothelin (Bosentan) and
analogs of prostacyclin (Iloprost) [1,3-5]. Not always, as
in our case, the ulcers heal with systemic treatment; for
this reason and because of the beneficial effects on heal-
ing of infected vasculitic lesions, it was decided to treat
this patient’s refractory ulcer using the hyperbaric oxy-
gen (HBO) [2,6,7]. A case of SLE complicated by vascu-
litic ulcers initially treated unsuccessfully with high
doses of steroids and immunosuppressants (mycopheno-
late mofetil and cyclophosphamide) showing a signifi-
cant improvement after only 2 doses of rituximab, 3
months of methotrexate and 1 month of HBOT has
been recently described in a female adult [7]. Moreover,
a recent study evaluated the effects of HBOT on 35
adult patients with refractory vasculitic skin ulcers that
were not responding to immunosuppressive therapy.
Seven of these 35 patients had SLE. The treatment
included four weeks of HBO (5 weekly sessions of 90
minutes at 2 ATA). Satisfactory results were obtained:
at the end of hyperbaric therapy 28 patients (80%) were
completely cured, four (11.4%) only partially, and in
three (8.6%) there was no improvement. Only one of
these three patients who did not respond to the hyper-
baric treatment had SLE. None of these 35 patients had
side effects and all of them tolerated the hyperbaric
therapy well [2]. In this study, authors used the Univer-
sity of Texas Wound Classification System to evaluate
ulcer severity [8]. HBO is a treatment that consists of
the administering of 100% pure oxygen in a pressurized
chamber to an absolute atmosphere (ATA) greater than
1, leading to an increase in the amount of free oxygen
in the plasma, creating a diffusion gradient that facili-
tates the transition of oxygen from the capillaries to the
ischemic tissues. It is particularly effective against anae-
robic bacteria facilitating the killing by leukocytes, and
increasing the effectiveness of various antibiotics by
acting in synergy. It also promotes the deposition of
collagen, angiogenesis, epithelialization and exerts bene-
ficial effects on vascular inflammatory response, redu-
cing the adhesion of neutrophils in the microcirculation
[9-11]. HBO exerts its anti-bacterial effect facilitating
the oxygen-dependent peroxidase system by which leu-
kocytes kill bacteria and increasing generation of oxygen
free radicals which oxidize proteins and membrane
lipids, damage deoxyribonucleic acid (DNA) and inhibit
metabolic functions of bacteria. HBOT also improves
the oxygen-dependent transport of certains antibiotics
across bacterial cell walls, particularly aminoglycosides
[9,10]. Several studies show that HBO increases the pro-
liferation of fibroblasts and endothelial cells and it also
induces the differentiation and migration of keratino-
cytes. Moreover, fibroblasts need oxygen tensions to
deposit collagen properly and the production of collagen
is proportional to oxygen tensions. The major enzymes
(prolyl hydroxylase, lysil hydroxylase, lysil oxydase)
involved in the post-translational steps of collagen
synthesis require oxygen as a cofactor. In fact, oxygen is
needed for lysine and proline hydroxylation, a step
required for the collagen release from cells. Without
oxygen, the underhydroxylated pro-alpha peptide chains
fail to form a triple helix. Prolyl hydroxylase is required
not only for hydroxyproline synthesis but is also essen-
tial for triple helix formation, while lysil hydroxylase and
lysil oxidase allow for proper collagen cross-linking. It
has been experimentally demonstrated that vascular
endothelial growth factor (VEGF) increases its expres-
sion in both hypoxic and hyperoxic conditions, but
angiogenesis proceeds more efficiently and it can only
be maintained with sufficient oxygen tensions [11].
Oxygen stimulates reepithelization via reactive oxygen
species (ROS), which are necessary for the function of
growth factors, such as the epidermal growth factor
(EGF) [11], and hyperoxia decreases edema in the peri-
wound area through its vasoconstrictive action [9]. HBO
acts on an important pathogenic mechanism because it
reduces rolling and adhesion of polymorphonuclear cells
in the microcirculation, affecting polymorphonuclear-
endothelial cell adhesion via the modification of CD
receptors, thus downregulating the functions of CD11/
18 [2]. In fact, it is thought that the increased expression
of vascular adhesion molecules have an important role
in the pathogenesis of vasculitis secondary to connective
t i s s u ed i s e a s e s[ 1 ] .O x y g e nt h e r a p yi sg e n e r a l l ys a f ea n d
well tolerated [2]. Side effects are generally mild and
reversible, and rarely occur if the applied pressure is less
Figure 3 Toe as it appears after 32 sessions of HBO therapy.
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ited to a maximum of 120 minutes [12]. Possible com-
plications are given by barotraumatic lesions, oxygen
toxicity, confinement anxiety, myopia, and cataracts
[9-11]. Absolute contraindications for this treatment
method are untreated pneumothorax and use of che-
motherapy. Relative contraindications include known
malignancies, pregnancy, implanted pacemakers, upper
respiratory infections, chronic sinusitis, epilepsy, emphy-
sema, hyperthermia, history of thoracic surgery, optic
neuritis, otosclerosis, viral infections and congenital
spherocytosis [10].
Conclusion
We decided to start HBOT before adding other immu-
nosuppressants to the basic therapy, because these drugs
are sometimes ineffective and not free from side effects,
and also because the patient, other than her vasculitic
ulcer, had no signs of disease activity and her blood-
chemical indices were normal. Our case demonstrates
the usefulness and effectiveness of this treatment in
healing infected ischemic lesions. Before starting the
cycle of hyperbaric oxygen, the patient’s ulcer was grade
1 (superficial wound with involvement of the dermis
and skin, but without compromising joint, tendon or
bone) and stage D (ischemic wound infection), accord-
ing to the classification system of wounds of the Univer-
sity of Texas. At the end of the sessions, the lesion
became Grade 0 (healed ulcer) and stage A (no signs of
suffering disease or infection). The lack of serious side
effects and relatively low cost makes this treatment ben-
eficial for patients with ischemic vasculitic ulcers. Cur-
rently, case-control or retrospective studies on the
effectiveness of HBOT in young patients with SLE com-
plicated by vasculitic skin ulcers have not been listed
until now. Considering the potential complications and
the lack of large retrospective studies or case-control
studies, further research is needed to determine its
effectiveness and its role as primary therapy for vasculi-
tic ulcers both in pediatric patients and adults.
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